Low-Dose Tirzepatide Produces Meaningful Weight Loss in Just 12 Weeks in Real-World Use
A real-world study of 115 adults with obesity (no diabetes) found significant weight loss with low-dose tirzepatide (2.5-5mg) in just 12 weeks.
Quick Facts
What This Study Found
Low-dose tirzepatide (2.5-5mg) produced significant weight loss and metabolic improvements in 12 weeks in adults with obesity without diabetes.
Key Numbers
How They Did This
Prospective multicenter observational study; 115 adults with obesity without diabetes; tirzepatide 2.5mg (4 weeks) then 5mg (8 weeks); anthropometric and biochemical assessments.
Why This Research Matters
Real-world evidence at lower doses and shorter durations helps set realistic expectations for patients starting tirzepatide and supports cost-effective prescribing.
The Bigger Picture
Demonstrating effectiveness at lower doses may help address supply constraints and cost barriers that limit access to tirzepatide for many patients.
What This Study Doesn't Tell Us
No control group; observational design; 12 weeks is short for assessing sustainable weight loss; small sample.
Questions This Raises
- ?Is weight loss sustained or does it plateau at these lower doses?
- ?How do these real-world results compare to clinical trial data at equivalent doses?
Trust & Context
- Key Stat:
- Significant weight loss at 12 weeks Low-dose tirzepatide (2.5-5mg) effective in real-world obesity treatment
- Evidence Grade:
- Prospective observational study — provides real-world effectiveness data but lacks randomization and placebo control.
- Study Age:
- Published 2026 in International Journal of Obesity.
- Original Title:
- A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.
- Published In:
- International journal of obesity (2005), 50(3), 684-688 (2026)
- Authors:
- Angelopoulos, Nikolaos(2), Androulakis, Ioannis(2), Rizoulis, Andreas(2), Boniakos, Anastasios, Fousteris, Evangelos, Mentzelopoulou, Voula, Petkova, Valentina, Paparodis, Rodis, Zianni, Dimitra, Florakis, Dimos, Korakovouni, Areti, Mouslech, Zadalla, Livadas, Sarantis, Tzoulis, Ploutarchos
- Database ID:
- RPEP-14771
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide work at low doses?
Yes — this study found that even the lowest doses (2.5mg and 5mg) produced significant weight loss within 12 weeks in people with obesity who don't have diabetes.
How quickly does tirzepatide start working?
This study showed meaningful weight loss and metabolic improvements within just 12 weeks at starting doses, suggesting benefits begin early in treatment.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14771APA
Angelopoulos, Nikolaos; Androulakis, Ioannis; Rizoulis, Andreas; Boniakos, Anastasios; Fousteris, Evangelos; Mentzelopoulou, Voula; Petkova, Valentina; Paparodis, Rodis; Zianni, Dimitra; Florakis, Dimos; Korakovouni, Areti; Mouslech, Zadalla; Livadas, Sarantis; Tzoulis, Ploutarchos. (2026). A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.. International journal of obesity (2005), 50(3), 684-688. https://doi.org/10.1038/s41366-025-01986-0
MLA
Angelopoulos, Nikolaos, et al. "A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.." International journal of obesity (2005), 2026. https://doi.org/10.1038/s41366-025-01986-0
RethinkPeptides
RethinkPeptides Research Database. "A real-world study of tirzepatide for weight loss in adults ..." RPEP-14771. Retrieved from https://rethinkpeptides.com/research/angelopoulos-2026-a-realworld-study-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.